Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4
D Bumbaca, A Wong, E Drake, AE Reyes II, BC Lin… - MAbs, 2011 - Taylor & Francis
Off-target binding can significantly affect the pharmacokinetics (PK), tissue distribution,
efficacy and toxicity of a therapeutic antibody. Herein we describe the development of a
humanized anti-fibroblast growth factor receptor 4 (FGFR4) antibody as a potential
therapeutic for hepatocellular carcinoma (HCC). A chimeric anti FGFR4 monoclonal
antibody (chLD1) was previously shown to block ligand binding and to inhibit FGFR4
mediated signaling as well as tumor growth in vivo. A humanized version of chLD1, hLD1 …
efficacy and toxicity of a therapeutic antibody. Herein we describe the development of a
humanized anti-fibroblast growth factor receptor 4 (FGFR4) antibody as a potential
therapeutic for hepatocellular carcinoma (HCC). A chimeric anti FGFR4 monoclonal
antibody (chLD1) was previously shown to block ligand binding and to inhibit FGFR4
mediated signaling as well as tumor growth in vivo. A humanized version of chLD1, hLD1 …
以上显示的是最相近的搜索结果。 查看全部搜索结果